Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CANbridge Files China NDA for Hunter Syndrome Drug

publication date: Jul 29, 2019

CANbridge Pharma of Beijing filed an NDA in China for a rare disease treatment that targets Hunter Syndrome. Hunterase (idursulfase beta) is a human recombinant iduronate-2-sulfatase (IDS) enzyme replacement therapy. CANbridge in-licensed China rights to the candidate from GC Pharma of Korea in January of this year. The drug is already available in ten countries. Hunter Syndrome is a rare and often fatal genetic disease that occurs more frequently in Asia than in the West. More details....

Stock Symbol: (KRX: 006280)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.